Biomolecules
Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.
Journal Title
Biomolecules
BIOMOLECULES
ISSN / eISSN
2218-273X / 2218-273X
Aims and Scope
Biomolecules (ISSN 2218-273X) is an international, peer-reviewed open access journal focusing on biogenic substances and their biological functions, structures, interactions with other molecules, and their microenvironment as well as biological systems. Biomolecules publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
Subject Area
BIOCHEMISTRY & MOLECULAR BIOLOGY
CiteScore
8.30
View Trend
CiteScore Ranking
Category | Quartile | Rank |
---|---|---|
Biochemistry, Genetics and Molecular Biology - Biochemistry | Q1 | #94/428 |
Biochemistry, Genetics and Molecular Biology - Molecular Biology | Q2 | #114/380 |
Web of Science Core Collection
Science Citation Index Expanded (SCIE) | Social Sciences Citation Index (SSCI) |
---|---|
Indexed | - |
Category (Journal Citation Reports 2023) | Quartile |
---|---|
BIOCHEMISTRY & MOLECULAR BIOLOGY - SCIE | Q1 |
Country/Area of Publication
Switzerland
Publisher
MDPI (Basel, Switzerland)
Year Publication Started
2011
Annual Article Volume
1843
Open Access
YES
Contact
ST ALBAN-ANLAGE 66, BASEL, SWITZERLAND, CH-4052
Verified Reviews
Pending review (Aug 26)
Under review (Aug 30)
Pending major revision (Sep 19)
Resubmit 1st round (Oct 4)
Pending minor revision (Oct 8)
Resubmit 2nd round (Oct 10)
Pending editor decision (Oct 10)
Accept (Oct 12)
Proof resubmit (Oct 14)
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now